内皮细胞钙蛋白酶选择性缺失通过改善血管新生减轻糖尿病心肌病
该研究通过内皮细胞特异性Capns1敲除小鼠,在模拟糖尿病前期、1型和2型糖尿病的模型中探讨内皮细胞钙蛋白酶在糖尿病心肌病中的作用。结果显示,内皮细胞钙蛋白酶缺失可减少心脏纤维化和肥厚、改善心肌功能障碍,且不显著影响全身代谢变量,机制涉及β-catenin上调促进血管新生和抑制凋亡。
要点
- 内皮细胞钙蛋白酶缺失可减轻糖尿病小鼠心肌功能障碍和心脏纤维化、肥厚。
- 保护作用与心肌毛细血管密度和冠脉血流储备增加相关。
- 机制涉及钙蛋白酶抑制β-catenin,抑制钙蛋白酶可促进血管新生、减少凋亡。
核心结论
- 内皮细胞钙蛋白酶通过抑制β-catenin诱导心脏内皮细胞损伤和血管新生障碍,从而促进糖尿病心肌病。
- 钙蛋白酶是预防糖尿病心脏并发症的有前景的治疗靶点。
研究设计与样本
- 研究构建内皮细胞特异性Capns1敲除小鼠,并在其与野生型同窝对照中诱导模拟糖尿病前期、1型和2型糖尿病的条件。
- 采用超声心动图评估心肌功能和冠脉血流储备,组织学分析毛细血管密度、心肌细胞大小和纤维化,离体主动脉环检测血管新生,培养心脏微血管内皮细胞给予高棕榈酸酯刺激分析血管新生和凋亡。
主要发现
- 内皮细胞特异性Capns1缺失破坏内皮细胞中钙蛋白酶1和钙蛋白酶2,减少心脏纤维化和肥厚,缓解糖尿病小鼠模型的心肌功能障碍,而不显著影响全身代谢变量。
- 毛细血管密度在糖尿病前期野生型 vs Capns1-KO为3646.14 ± 423.51 vs 4708.7 ± 417.93 capillary number/high-power field,2型糖尿病为2999.36 ± 854.77 vs 4579.22 ± 672.56 capillary number/high-power field,1型糖尿病为2364.87 ± 249.57 vs 3014.63 ± 215.46 capillary number/high-power field。
- 离体血管新生分析显示糖尿病前期和糖尿病Capns1-KO小鼠主动脉环内皮细胞 sprouts 多于野生型同窝对照。
- 培养心脏微血管内皮细胞中,钙蛋白酶抑制改善代谢应激下的血管新生并防止凋亡。
- 机制上,Capns1缺失升高Capns1-KO小鼠内皮细胞β-catenin蛋白水平,而钙蛋白酶2组成性活性抑制培养内皮细胞β-catenin蛋白表达;上调β-catenin促进血管新生和抑制凋亡,而敲低β-catenin抵消钙蛋白酶抑制的保护作用。
临床怎么用
- 内皮细胞钙蛋白酶可作为预防糖尿病心脏并发症的潜在治疗靶点。
- 保护作用不依赖全身代谢变量改善,提示靶向血管内皮可能独立于降糖获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The role of non-cardiomyocytes in diabetic cardiomyopathy has not been fully addressed. This study investigated whether endothelial cell calpain plays a role in myocardial endothelial injury and microvascular rarefaction in diabetes, thereby contributing to diabetic cardiomyopathy. METHODS: Endothelial cell-specific Capns1-knockout (KO) mice were generated. Conditions mimicking prediabetes and type 1 and type 2 diabetes were induced in these KO mice and their wild-type littermates. Myocardial function and coronary flow reserve were assessed by echocardiography. Histological analyses were performed to determine capillary density, cardiomyocyte size and fibrosis in the heart. Isolated aortas were assayed for neovascularisation. Cultured cardiac microvascular endothelial cells were stimulated with high palmitate. Angiogenesis and apoptosis were analysed. RESULTS: Endothelial cell-specific deletion of Capns1 disrupted calpain 1 and calpain 2 in endothelial cells, reduced cardiac fibrosis and hypertrophy, and alleviated myocardial dysfunction in mouse models of diabetes without significantly affecting systemic metabolic variables. These protective effects of calpain disruption in endothelial cells were associated with an increase in myocardial capillary density (wild-type vs Capns1-KO 3646.14 ± 423.51 vs 4708.7 ± 417.93 capillary number/high-power field in prediabetes, 2999.36 ± 854.77 vs 4579.22 ± 672.56 capillary number/high-power field in type 2 diabetes and 2364.87 ± 249.57 vs 3014.63 ± 215.46 capillary number/high-power field in type 1 diabetes) and coronary flow reserve. Ex vivo analysis of neovascularisation revealed more endothelial cell sprouts from aortic rings of prediabetic and diabetic Capns1-KO mice compared with their wild-type littermates. In cultured cardiac microvascular endothelial cells, inhibition of calpain improved angiogenesis and prevented apoptosis under metabolic stress. Mechanistically, deletion of Capns1 elevated the protein levels of β-catenin in endothelial cells of Capns1-KO mice and constitutive activity of calpain 2 suppressed β-catenin protein expression in cultured endothelial cells. Upregulation of β-catenin promoted angiogenesis and inhibited apoptosis whereas knockdown of β-catenin offset the protective effects of calpain inhibition in endothelial cells under metabolic stress. CONCLUSIONS/INTERPRETATION: These results delineate a primary role of calpain in inducing cardiac endothelial cell injury and impairing neovascularisation via suppression of β-catenin, thereby promoting diabetic cardiomyopathy, and indicate that calpain is a promising therapeutic target to prevent diabetic cardiac complications.
引用
- Teng X, Ji C, Zhong H, et al. Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis. Diabetologia. 2019. PMID: 30778623. doi:10.1007/s00125-019-4828-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。